Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Aims Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel
oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and …
oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and …
An update on betrixaban, the challenging anticoagulant agent for extended venous thromboembolism prophylaxis
Y Daryabari, F Amreek… - Journal of …, 2022 - journals.lww.com
Venous thromboembolism (VTE) is a prevalent yet preventable cause of death, particularly
among hospitalized patients. Studies have shown that the risk of VTE remains high for up to …
among hospitalized patients. Studies have shown that the risk of VTE remains high for up to …
The current place of direct oral anticoagulants in the prevention/treatment of venous thromboembolism
M Tomić - Archives of Pharmacy, 2020 - aseestant.ceon.rs
Venous thromboembolism (VTE; includes deep venous thrombosis, DVT, and pulmonary
embolism, PE) represents the third most common acute cardiovascular syndrome …
embolism, PE) represents the third most common acute cardiovascular syndrome …
[引用][C] Mesto direktnih oralnih antikoagulansa u prevenciji/lečenju venskog tromboembolizma
M Tomić - Arhiv za farmaciju, 2020 - … of Serbia, Belgrade and University of …